US 12,185,740 B2
Polypeptides having xylanase activity and polynucleotides encoding same
Charlotte Blom, Lynge (DK); Ninfa Rangel Pedersen, Soeborg (DK); Dan Pettersson, Lynge (DE); Jens Magnus Ekloef, Copenhagen (DK); Kristian Bertel Roemer Krogh, Bagsvaerd (DK); Martin Simon Borchert, Hilleroed (DK); Dorotea Raventos Segura, Rungsted (DE); Nele Ilmberger, Hamburg (DE); Wolfgang Streit, Monkeburg (DE); and Jesper Salomon, Holte (DE)
Assigned to Novozymes A/S, Bagsvaerd (DK)
Filed by Novozymes A/S, Bagsvaerd (DK)
Filed on Sep. 7, 2022, as Appl. No. 17/930,203.
Application 17/930,203 is a division of application No. 17/063,112, filed on Oct. 5, 2020, granted, now 11,470,859.
Application 17/063,112 is a division of application No. 16/254,767, filed on Jan. 23, 2019, granted, now 10,842,172, issued on Nov. 24, 2020.
Application 16/254,767 is a division of application No. 15/323,548, granted, now 10,258,065, issued on Apr. 16, 2019, previously published as PCT/EP2015/065754, filed on Jul. 9, 2015.
Claims priority of application No. 14176473 (EP), filed on Jul. 10, 2014; and application No. 14184066 (EP), filed on Sep. 9, 2014.
Prior Publication US 2023/0148423 A1, May 11, 2023
Int. Cl. C12N 9/24 (2006.01); A23K 20/10 (2016.01); A23K 20/147 (2016.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 15/82 (2006.01); C12P 19/02 (2006.01); C12P 19/14 (2006.01)
CPC A23K 20/147 (2016.05) [A23K 20/10 (2016.05); C12N 9/2477 (2013.01); C12N 9/2482 (2013.01); C12N 15/8245 (2013.01); C12P 19/02 (2013.01); C12P 19/14 (2013.01); C12Y 302/01008 (2013.01); C12Y 302/01055 (2013.01); C07K 2319/02 (2013.01); C07K 2319/21 (2013.01)] 23 Claims
 
1. A recombinant host cell comprising a polynucleotide encoding a polypeptide having xylanase activity,
wherein the polynucleotide is operably linked to one or more heterologous control sequences that direct the production of the polypeptide in the recombinant host cell and/or the polynucleotide is heterologous to the recombinant host cell,
wherein the polypeptide having xylanase activity meets at least one of the following criteria:
a) comprises the amino acid sequence of SEQ ID NO: 73;
b) comprises an amino acid sequence that has at least 99.0% sequence identity to the amino acid sequence of SEQ ID NO: 73;
c) is a fragment of SEQ ID NO: 73 that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 73, and
wherein sequence identity is calculated using an EBLOSUM62 substitution matrix, an open gap penalty of 10 and a gap extension penalty of 0.5.